RE: All is goodOnce that deal is done, we are back to a 2 blockbuster product company.
Beyond stupid once again. An orphan drug by definition cannot be a blockbuster. And for 232, will it be the same kind of blockbuster as 4601???!! They just don't have the money to drive it by themselves anyways. New CEO told it. They are now focused on their orphan, small market drug. Also, CEO said that they will need to assess the patients 2 months after administration of Shigamabs. The trial will be in two parts, with two cohorts, with two months to wait after each cohort for the final assessment of patients, plus time for data analysis, plus the recruitment and treatment time. WOW!!!! This phase II will take more than 6 months to be completed, and again, safety will be the primary endpoint. Not efficacy. So the lobsters will need to wait in three years to finally know if this candidate is efficacious, without knowing the study desing for phase II, and efficacy endpoint. Three years in a cage with Dumbo!!!!! OUCH!!!!! YUP YUP YUP!!!!!
Also. They will submit a modified protocol. I don't care if Chile and Argentina accept it. The important question is: Will FDA accept it? LFB don't care about FDA, and they are those paying for all that. When you pay. You lead the show. The bride is always beautiful before the wedding!!!!!
So, in short. Buy now, and hope for a positive answer in three year, if the project is not stopped before.